Nuformix PLC Result of General Meeting and Total Voting Rights (8160T)
March 29 2021 - 5:27AM
UK Regulatory
TIDMNFX
RNS Number : 8160T
Nuformix PLC
29 March 2021
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS
RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN
WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE
UNITED STATES, AUSTRALIA,
CANADA, JAPAN, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH
AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION
OR DISTRIBUTION WOULD BE UNLAWFUL.
Nuformix plc
("Nuformix" or the "Company")
Result of General Meeting
and
Total Voting Rights
London, UK - 29 March 2021: Nuformix plc (LSE:NFX), a
pharmaceutical development company targeting unmet medical needs in
fibrosis and oncology via drug repurposing, confirms that, further
to the announcement made in connection with the Placing on 10 March
2021, at the General
Meeting held earlier today all Resolutions put to Shareholders
were duly passed.
Accordingly, the Company has raised, in aggregate, gross
proceeds of GBP1.565 million.
Applications have been made to the FCA for the Placing Shares to
be admitted to the Official List and to the London Stock Exchange
for the Placing Shares to be admitted to trading on the Main Market
of the London Stock Exchange. It is expected that Admission will
become effective at 8:00 a.m. on 30 March 2021 and that dealings in
the Placing Shares will commence at that time.
Total Voting Rights
On Admission, the Company will have 591,609,368 Ordinary Shares
in issue, each with one voting right. There are no shares held in
treasury. Therefore, the Company's total number of Ordinary Shares
and voting rights will be 591,609,368 and this figure may be used
by Shareholders from Admission as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Unless otherwise defined, all capitalised terms used but not
defined in this announcement shall have the meaning given to them
in the Circular dated 10 March 2021, a copy of which is available
to view on the Company's website (www.nuformix.com).
Enquiries:
Nuformix plc
Dr Anne Brindley, CEO
Fleur Wood, Investor Relations
+44 (0)1223 627222
Allenby Capital Limited
Tim Sohal / Matt Butlin (Sales and Corporate
Broking)
Nick Athanas / George Payne (Corporate Finance) +44 (0)203 328 5656
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMUKURRANUOUAR
(END) Dow Jones Newswires
March 29, 2021 06:27 ET (10:27 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2023 to Apr 2024